Nov 30 2009
At the invitation of the Food and Drug Administration, Stan Valencis, President of Acsys Interactive, recently presented a series of recommendations to help shape the government's policy towards the promotion of prescription drugs, biologics and medical devices using the Internet and social media tools. As a leader in providing digital marketing and interactive strategies to healthcare systems, hospitals, device manufacturers and pharmaceutical companies, Acsys Interactive was selected by the FDA to provide its uniquely qualified perspective and experience.
"Social media is rapidly becoming an integral source of medical information to millions of consumers seeking to improve their overall health and find effective treatment options," states Stan Valencis. "We appreciate the FDA's invitation to present our recommendations and their collaborative approach in seeking the recommendations of leaders across the healthcare industry. While technology is changing quickly and as such, needs to be reacted to quickly, we must maintain a balanced approach that encourages innovation while also ensuring the protection of consumers from sources of misinformation accessible via the Internet."
The key messages from Stan Valencis' testimony at the FDA's public hearings conducted in Washington, DC on November 12th and 13th include:
-- Growing Importance of Social Media in Society
-- Adoption of Social Media Amongst Healthcare Marketing Organizations
-- Biggest Obstacles to Adoption Are Transparency, Liability and Best Practices
-- Establish Authenticity of Medical Content with Introduction of FDA Seal of Approval
Full Details: Acsys Interactive's FDA Recommendations
Read the Company's detailed press release or watch Stan Valencis speak to the FDA as the government agency evaluates special characteristics of Web 2.0 and other emerging technologies that may require the agency to provide additional guidance to the industry on how the regulations should be applied.